Artificial intelligence is increasingly shaping molecular imaging and theranostics, from image reconstruction, segmentation and quantitative analysis to dosimetry, treatment planning and outcome prediction. This category covers the development, validation and clinical application of AI and machine-learning approaches across the theranostic pathway.

This category covers fundamental and translational research advancing our understanding of radiopharmaceutical diagnostics and therapy. Topics include radiobiological mechanisms, cellular and molecular responses to radiation, preclinical models, biomarker development and studies translating laboratory findings into new diagnostic or therapeutic approaches.

Combining radiopharmaceutical therapies with other treatment modalities may improve efficacy, overcome resistance and expand therapeutic options. This category includes combinations with immunotherapy, chemotherapy, targeted agents, DNA damage response inhibitors, external beam radiotherapy and other emerging treatment strategies.

New concepts continue to expand the scope of theranostics beyond established targets and treatment paradigms. This category provides a platform for innovative diagnostic and therapeutic strategies, novel technologies and early-stage approaches that may shape the future of Radiomolecular Precision Medicine.

The translation of theranostics into routine patient care depends on appropriate guidelines, regulatory frameworks, infrastructure and equitable access. This category addresses clinical implementation, health policy, reimbursement, patient selection, access to radiopharmaceuticals and therapies, and strategies for integrating theranostics into healthcare systems worldwide.

Advances in imaging and detection technologies are central to the continued development of theranostics. This category covers PET, SPECT and hybrid imaging systems, total-body and high-sensitivity imaging, detector technologies, image reconstruction and other instrumentation supporting improved diagnosis, quantification and therapy monitoring.

Medical physics and dosimetry provide the quantitative foundation for personalized radiopharmaceutical therapy. Topics include patient-specific dosimetry, quantitative imaging, absorbed-dose calculations, treatment planning, dose–response relationships, standardization and new methods for optimizing therapeutic efficacy while limiting toxicity.

The clinical translation of new molecular targets is expanding the range of cancers and other diseases accessible to theranostic approaches. This category covers first-in-human studies, clinical trials and other patient-based investigations evaluating novel targets, radiopharmaceuticals and target-specific diagnostic or therapeutic strategies.

Preclinical research is essential for identifying and validating the next generation of theranostic targets. This category includes target discovery and characterization, ligand development, in vitro and in vivo evaluation, biodistribution, pharmacokinetics and proof-of-concept studies supporting future clinical translation.

Theranostic strategies increasingly extend across a broad spectrum of solid tumors and established molecular targets beyond the major dedicated categories. This category covers clinical and translational research involving established target systems and tumor entities not specifically addressed elsewhere within the TWC2027 abstract topics.

PSMA-targeted imaging and radioligand therapy have established theranostics as an important component of prostate cancer management. This category covers PSMA PET imaging, beta- and alpha-emitting radioligand therapies, patient selection, dosimetry, resistance mechanisms, treatment sequencing and emerging approaches across the prostate cancer pathway.

Innovations in radiochemistry enable the development of new diagnostic and therapeutic radiopharmaceuticals. This category includes radionuclide labelling, chelator and linker chemistry, synthesis and automation, quality control, novel radiopharmaceutical design and methods supporting efficient production and clinical translation.

Reliable access to diagnostic and therapeutic radionuclides is essential for the global expansion of theranostics. This category covers isotope production, accelerator and reactor technologies, generators, purification, supply chains, quality assurance and strategies to increase the availability and sustainability of medically relevant radioisotopes.

Somatostatin receptor-targeted imaging and therapy remain central to the management of neuroendocrine tumors. This category includes SSTR imaging, peptide receptor radionuclide therapy (PRRT), agonists and antagonists, beta- and alpha-emitting approaches, dosimetry, treatment optimization and strategies for patients with advanced or treatment-resistant disease.

Targeted alpha therapy offers highly localized, high-linear-energy-transfer radiation and is emerging as an important therapeutic strategy in precision oncology. This category covers alpha-emitting radionuclides, radiopharmaceutical development, clinical and preclinical applications, dosimetry, toxicity, production and approaches to improve treatment efficacy and safety.

The tumor microenvironment plays a critical role in cancer progression, treatment response and resistance. This category covers molecular imaging and targeted therapy of stromal, vascular and immune components, immune-related biomarkers, immuno-PET and theranostic strategies designed to characterize or modulate the tumor microenvironment.

This category welcomes high-quality research relevant to theranostics and Radiomolecular Precision Medicine that does not clearly fit within one of the defined TWC2027 abstract topics.